Longitudinal study of early nafld progression and the GUT microbiome in asian americans, native hawaiians and whites

Active Project Grant Awarded Last action

Award ID
R01MD018265
Recipient
Awarding agency
Obligated
$11,866,504

Award facts

Completion date 87% complete
Place of performance
Honolulu, HI 96813, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Non-alcoholic fatty liver disease (NAFLD) affects >35% of older adults in the US. IT is now the primary etiology of chronic liver disease and liver cancer, and the driver of the recent upward trend in these lethal diseases. A dysbiotic GUT microbiome has been associated with NAFLD, but mostly in small-scale, cross-sectional or clinic- based studies. Population-based longitudinal studies are needed to provide evidence for the temporal relationship of the GUT microbiome with the progression of NAFLD. In the cross-sectional multiethnic cohort (MEC) adiposity phenotype study (APS; P01 CA168530), we showed a significant difference in GUT microbial composition and inferred microbial function by NAFLD status, including enrichment of fusobacterium and endotoxin-producing bacteria and altered microbial pathways for bile acid and simple carbohydrate metabolism in NAFLD. We now hypothesize that specific GUT bacterial features (genera, metabolic pathways and blood endotoxin biomarker lipopolysaccharide binding protein (LBP)) are associated with increase in liver FAT and liver fibrosis over time. We also hypothesize that several dietary factors are associated with NAFLD progression and that fibrosis-promoting GUT bacterial features mediate these associations. We propose a longitudinal investigation by efficiently adding a ~10-year follow-up assessment among 300 of the MEC-APS participants, aged 60-77 years at baseline and of three racial/ethnic groups (japanese american, native hawaiian or white), across a wide range of baseline liver FAT. We will RE-assess liver FAT using MRI and measure liver stiffness using MR elastography, gold-standard methods for non-invasive quantification of liver FAT and liver stiffness, respectively, and perform 16S rrna gene sequencing (follow-up stool samples) and metagenomic sequencing (baseline and follow-up stool samples). Specific aims are to: 1) evaluate the change in specific GUT bacterial features (abundance of genera, metabolic pathways, and LBP) over time in relation to the change in liver FAT; 2) evaluate the change in GUT bacterial features over time in relation to (2A) liver stiffness at follow-up and (2B) change in a blood biomarker panel for liver fibrosis (enhanced liver fibrosis (ELF) score), and (2C) validate the top two bacterial features associated with liver stiffness using ddpcr; and 3) assess the association of diet (3 dietary pattern scores for overall diet quality and 7 key components) with ELF-based change in liver fibrosis and explore the mediation by fibrosis-promoting GUT bacterial features from aim 2, stratified by liver FAT level. Our results will identify GUT microbial features associated with early NAFLD progression, while specifically addressing the needs of understudied asian americans and native hawaiians (not-HL-23-001), two high-risk populations for NAFLD and liver cancer. The strengths of the proposed longitudinal design and rigorous imaging and laboratory methods will aid in understanding NAFLD progression involving the GUT microbiome. These findings may be used to inform novel targeted intervention strategies to prevent NAFLD progression and, ultimately, reduce liver cancer burden in multiple racial/ethnic populations.

Transactions

Action Obligated Date
Amendment $62,597
Amendment $0
Amendment $391,250
Amendment $632,485
Amendment $632,485
Amendment $115,080
Amendment $634,776
Amendment $0
Amendment $0
Amendment $0
Amendment $6,183
Amendment $6,183
Amendment $6,183
Amendment $6,183
Amendment $6,183
Amendment $52,483
Amendment $52,483
Amendment $52,483
Amendment $52,483
Amendment -$9,025
Amendment -$9,025
Amendment -$9,025
Amendment -$9,025
Amendment -$9,025
Amendment $410,237
Amendment $410,237
Amendment $410,237
Amendment $410,237
Amendment $410,237
Amendment $410,237
Amendment $666,558
Amendment $666,558
Amendment $666,558
Amendment $666,558
Amendment $666,558
Amendment $666,558
Amendment $666,558
Amendment $687,172
Amendment $687,172
Amendment $0
Amendment $0
Amendment $0
Original award $700,437
Show all 43

Subawards

Subrecipient Amount Awarded
Fred Hutchinson Cancer Center Longitudinal Study of Early NAFLD Progression and the Gut Microbiome in Asian Americans, Native Hawaiians and Whites $62,597
Fred Hutchinson Cancer Center $115,080
Fred Hutchinson Cancer Center $337,719
Fred Hutchinson Cancer Center $58,666
Fred Hutchinson Cancer Center $43,887
Fred Hutchinson Cancer Center $221,400
Fred Hutchinson Cancer Center $189,952

Quick answers

Who received award R01MD018265?

R01MD018265 was awarded to University Of Hawaii by National Institute for Minority Health and Health Disparities (National Institutes of Health) on September 26, 2022.

How much is award R01MD018265 worth?

$11,866,504 has been obligated on R01MD018265.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login